LACunar Intervention (LACI-2) Trial-2

A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 363 participants.

Also called NCT03451591

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose prevention
Phase
Phase 2/3
Enrolled
  • 363 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03451591
  • EudraCT 2016-002277-35
Other papers using this trial's data
  • Isosorbide Mononitrate and Cilostazol Treatment in Patients With Symptomatic Cerebral Small Vessel Disease: The Lacunar Intervention Trial-2 (LACI-2) Randomized Clinical Trial JAMA neurology, 2023-07-01 DOI, PubMed 37222252, PMC10209826 In the PMC Open Access subset under CC BY.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03451591. Randomized; single masking; primary purpose prevention. Start 2018-01-08 (actual); primary completion 2022-05-31 (actual). Results posted on 2024-11-12.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
LACunar Intervention (LACI-2) Trial-2
Acronym
LACI-2
Condition
Cerebral Small Vessel Diseases
Condition
Stroke, Lacunar
Intervention (Drug)
Isosorbide Mononitrate XL (ISMN)
Intervention (Drug)
Cilostazol
Intervention (Drug)
ISMN XL and Cilostazol
Intervention (Other)
Neither ISMN nor cilostazol
Lead sponsor
University of Edinburgh (class: other)
Collaborator
British Heart Foundation (class: other)
Collaborator
University of Nottingham (class: other)

Record details

Record id
cardio:ct-nct03451591
Content hash
8f599f38af40114559d9f5125511919155774dcaa2c8fcb1c7b5d108e1387585